Pfizer will end development of weight-loss pill over fears about its impact to the liver
Drugmaker Pfizer has announced its decision to discontinue the development of its experimental daily pill to treat obesity.
The move comes after a patient in a trial suffered a liver injury potentially caused by the oral GLP-1 drug known as danuglipron.
The patient, who was not identified, did not experience any symptoms and their injury 'resolved' after they stopped taking the drug.
'While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients,' Pfizer's Chief Scientific Officer Dr. Chris Boshoff said in a statement.
The Swiss company reviewed all clinical data for danuglipron and recent input for regulators before making their decision.
Its statement also suggested the patient's liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial rapidly increased the dose of the pill over a short span of time.
The company had previously scrapped the development of a twice-daily version of the drug in 2023 after trial patients experienced vomiting and nausea.
A once-daily pill could have had a competitive edge over other weight loss drugs taken twice a day.
Several companies are developing weight loss pills after surging popularity of the shots that target an intestinal hormone called GLP-1. Ozempic and Wegoy are popular injectables related to CLP-1. Oral drugs are also considered to be easier to make than injectables, as well as easier to take.
Obesity is a serious and common chronic disease. In the U.S. more than two in five adults have obesity.
The investment bank Morgan Stanley said the global market for obesity drugs is expected to reach $105 billion by 2030 — and as high as $144 billion. Comparatively, it noted that sales of branded obesity drugs had totaled $6 billion in 2023.
Pfizer said that it would continue development of an experimental oral drug targeting a different hormone.
'Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs,' he added.
With reporting from The Associated Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
2 hours ago
- Health Line
GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds
GLP-1 drugs are associated with a higher risk of 'wet' age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially increased the longer people were prescribed a GLP-1 drug, particularly those containing semaglutide. GLP-1 medications like Ozempic and Wegovy have surged in popularity as weight loss treatments, but ophthalmologists say their potential risks to eye health are not well understood. GLP-1 drugs are linked to a significantly higher risk of developing neovascular or 'wet' age-related macular degeneration, according to new research. The study, conducted by researchers at the University of Toronto, found that people with type 2 diabetes who were prescribed GLP-1s were more than twice as likely to develop wet AMD as those who weren't. The study also found that the longer subjects were treated with these medications, the greater their risk of developing wet AMD. Neovascular age-related macular degeneration, commonly known as wet AMD, is the less common but more aggressive form of age-related macular degeneration, and a leading cause of irreversible vision loss among older adults in the United States. The findings, published on June 5 in JAMA Ophthalmology, suggest that doctors and patients should be aware of the potential risks, even though the chance of developing the condition remains relatively low. GLP-1 drugs, a class of blockbuster diabetes and obesity drugs sold under brand names like Ozempic and Wegovy, have surged in popularity in recent years. They offer a range of substantial benefits, including weight loss, improved blood sugar levels, and reduced cardiovascular disease risk. Despite these benefits, ophthalmologists say the impact of GLP-1 drugs on eye health is not well understood. Studies have identified an association between the medications and other eye conditions, including diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). While the findings don't establish a clear causal link between GLP-1 drugs and eye disease, experts say there's still reason for caution. 'The dose-response effect we observed — where longer GLP-1 receptor agonist exposure was associated with higher risk — strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors,' said study co-author Andrew Mihalache, MD(C), of the Temerty Faculty of Medicine at the University of Toronto, Canada. 'Seeing a graded relationship like this suggests that prolonged exposure could play a causal role in increasing risk. However, this needs to be confirmed in future studies,' he told Healthline. Long-term GLP-1 drug use may triple wet AMD risk Drawing on health records from Ontario, Canada, researchers at the University of Toronto analyzed nearly 140,000 adults with type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD. The retrospective study tracked patient outcomes over a three-year period, using data collected between 2020 and 2023. Roughly one-third of participants — about 46,000 people — had been prescribed a GLP-1 drug for at least six months. The rest had not. In the vast majority of cases (97.5%), that drug was semaglutide, the active ingredient in Ozempic and Wegovy. The average participant was 66, and the cohort was almost evenly divided by sex, with females representing 46.6% of the group. On average, those who were prescribed a GLP-1 drug were more than twice as likely to be diagnosed with wet AMD. However, that number doesn't tell the full story. People who took GLP-1 drugs for longer experienced progressively greater risk. Those who had only taken their medication for 6–18 months actually had a slightly lower risk than those who didn't take the medication. However, at the 18–30 month mark, GLP-1 users' risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk. 'This was definitely surprising, especially given the growing enthusiasm for GLP-1 receptor agonists for their cardiovascular and metabolic benefits. It really highlights the need for further investigation into their ocular safety profile,' first study author Reut Shor, MD, of the Department of Ophthalmology and Vision Sciences at the University of Toronto, Canada, told Healthline. Despite the increase in risk, the absolute risk of developing wet AMD was still low: 0.2% among those taking a GLP-1 and 0.1% among those who didn't. Do GLP-1 drugs harm eye health? While not definitive, the study raises further questions about the potential risks posed by GLP-1 drugs for eye health. Prior studies have also identified links between GLP-1s and other forms of eye disease in people with type 2 diabetes. In a major phase 3 semaglutide trial in 2016, researchers identified that type 2 diabetes patients taking semaglutide had a higher risk of complications of diabetic retinopathy compared to a placebo. Those findings were published in The New England Journal of Medicine. However, other studies have provided conflicting evidence. A retrospective 2024 study evaluated nearly 700 subjects with type 2 diabetes who were taking a GLP-1 drug and found no association between GLP-1s and worsening retinopathy. Also in 2024, researchers found that patients with type 2 diabetes who were prescribed semaglutide were at greater risk of NAION compared to those who weren't. NAION is a condition that causes sudden blindness, typically just in one eye, due to a lack of blood flow to the optic nerve. The mechanism for why GLP-1 drug use may lead to wet AMD is not well established, but a predominant theory is that lowering blood sugar rapidly leads to a lack of oxygen in the retina. 'When you make the retina more hypoxic, which is what the GLP-1s do, it basically pushes it further over the threshold, causing more abnormal blood vessels to grow,' said Linda Lam, MD, MBA, an ophthalmologist with Keck Medicine of USC, who wasn't involved in the research. Abnormal blood vessel growth in the eye is the hallmark of wet AMD. While GLP-1s offer many health benefits, eye disease risk must be considered in some populations, Lam told Healthline. 'In this particular group of patients who are older, who are diabetics, I really would caution against the extended use of GLP-1s,' she said. Lam reiterated the importance of annual eye exams for the general population, but in particular for those with diabetes, to identify and diagnose eye disease early on. People with type 2 diabetes, especially those taking a GLP-1 drug, should be aware of the signs and symptoms of vision loss and consult with their doctor immediately. These include:
Yahoo
3 hours ago
- Yahoo
46 State Medical Associations Urge Senate to Reject Medicaid Cuts in H.R. 1
The House Budget Reconciliation bill will cause at least 7.8 million Medicaid enrollees to lose their health care coverage. SACRAMENTO, Calif., June 6, 2025 /PRNewswire/ -- Just days ahead of an expected Senate vote on H.R. 1, 46 state medical associations, as part of Physicians for Medicaid have sent a letter to the United States Senate urging them to reject the dangerous cuts to Medicaid proposed in H.R. 1 that will cause millions of patients to lose coverage and even more to lose access to care - children, pregnant women, seniors, veterans, the disabled and working families. Statewide hospital associations have also weighed in, as proposed cuts impact all providers, including physicians and hospitals. The bill, which includes $200 billion in cuts to the existing and longstanding provider taxes, would have a catastrophic effect on state budgets and the country's entire health care delivery system and would impact 49 state Medicaid programs. Provider taxes have been authorized under federal law, approved by both Republican and Democratic administrations, and affirmed by state legislatures in 49 states for decades. They are a legitimate financing mechanism used by states in partnership with the federal government to fund essential health services and have kept rural hospitals, maternity wards, nursing homes, and physician practices open. The bill also imposes damaging changes to federal student loan programs making it harder for students to pursue medical careers at a time of critical physician shortages. We urge the Senate to pursue more balanced solutions that expand the physician workforce and preserve Medicaid for our patients. "If these provider tax cuts are enacted, it will create significant gaps in State budgets, forcing states to raise taxes, or reduce benefits, coverage, and provider payments. These reductions will lead to even more crowding of emergency departments and as the uncompensated care burdens grow from patients losing coverage, many rural hospitals, nursing homes, and community physician practices will be forced to close to all patients," the letter says. There are three main provisions in H.R. 1 (as passed by the House of Representatives on May 22, 2025) that will drastically limit or eliminate existing provider taxes nationwide. These provisions below apply to all provider taxes, including hospitals, nursing homes, managed care organizations, and other provider categories. Moratorium on New or Increased Provider Taxes (SEC. 44132) – Under the provisions of H.R. 1, none of these taxes could be increased after the passage and enactment of the law nor can any new taxes be adopted by the state Legislatures (there are 19 categories of provider taxes). This provision would freeze taxes and not keep pace with increasing health care costs over time. It is also not equitable between states. Revising Payments for Certain State Directed Payments (SEC. 44133) – Once a provider tax is established, state Medicaid programs can fund supplemental or enhanced payments to providers using a variety of rate methodologies. Under H.R. 1, any future directed payments would be limited to the Medicare payment rate. Medicare physician payment rates are already 33% behind the costs to provide health care. These rates will not keep pace for public hospitals and physician specialists that care for the sickest patients nationwide. Requirements Regarding Waiver of Uniform Tax Requirement for Medicaid Provider Tax (SEC. 44134) – The language in H.R. 1 requires provider taxes in multiple states to uniformly tax hospitals, nursing homes, and managed care organizations within each category of provider tax. The uniformity requirement will be extremely difficult for most states to meet and therefore, it eliminates multiple provider taxes in many states. The HHS Secretary has discretion to allow for a transition period, which is not something upon which states can rely. "These provisions will destabilize state health systems, reduce access to care, and worsen physician shortages. Instead, we encourage you to protect Medicaid – a proven, cost-effective safety net that serves 80 million vulnerable Americans," the letter concluded. View original content to download multimedia: SOURCE California Medical Association; Physicians for Medicaid Sign in to access your portfolio
CBS News
3 hours ago
- CBS News
Fire at Shell cracker plant in Beaver County forces evacuation of multiple employees
A spokesperson for the Pennsylvania Department of Environmental Protection said a fire at the Shell cracker plant in Beaver County forced the evacuation of multiple employees and potentially released chemicals into the community. Anita White and Eli Matich worry about what could be in the air outside their home in Potter Township, just miles away from the plant. "It just feels scary, because you don't really know how it's impacting your health," White said. "When they built it, it was meant for job employment, help boost Beaver County. But instead, it's kind of been more negative than positive, it seems like," Matich said. It was just two days ago when smoke appeared to be billowing out of the facility, caused by what the state DEP calls a fire. It happened Wednesday afternoon at ethane cracking furnace #5. The DEP spokesperson said Shell reported that 15 employees were evacuated, and one person suffered a minor heat-related injury. KDKA obtained a photo showing a mangled furnace inside the complex. A Shell employee told KDKA that the damage is so bad it could result in them tearing it down and rebuilding. "It's definitely concerning," Matich said. The DEP spokesperson said it resulted in the "possible release of an unknown amount of 1,3-butadiene and benzene" in the air, and that the furnace "was not in production at the time." The agency added that an emergency response team member conducted an initial assessment at the plant and did not see any visible emissions or unintended releases of them due to a malfunction or other problem, along with any unpleasant smells. Also, their "air monitor did not register any emissions above zero, which means there weren't any air pollutants that lingered related [to] the fire." "We're always trying to eat healthy and be clean, but then we have these chemicals that are going into the air. So, it kind of feels like, all right, what's the point?" White said. Environmental experts describe what may have been released this week as cancer-causing chemicals. Since Shell started operating here in late 2022, it's faced several malfunctions and millions of dollars in fines. Shell did not disclose the potential release of chemicals in a Facebook post to the public, but a spokesperson told KDKA they informed the Nuclear Regulatory Commission, and "will submit the [investigation] findings, as required, to the Pennsylvania Emergency Management Agency (PEMA) and the Local Emergency Planning Commission (LEPC)." As for White and Matich, for the time being, they'll be staying where they are. "Until the housing market gets a bit better, so we can move a little farther away," White said. The DEP spokesperson said Shell is continuing to investigate and that the agency will ensure the company complies with environmental regulations for the health and safety of the community.
